Broach Lifecare Hospital Ltd Directors Report

To, The Members

Your directors take pleasure in presenting the 3 rd Annual Report along with the Audited Financial Statement and Auditors report for the financial year ended March 31, 2026:

1. FINANCIAL HIGHLIGHTS

The financial performance of the Company during the year ended 31 st March, 2026 compared to the previous year is summarized below: (Rs. in Lakhs except EPS)

Particulars	2025-26	2024-25
Revenue from operations	599.47	317.94
Other income	4.20	4.58
Total Income	603.67	322.52
Less: Total Expenses	582.62	250.91
Profit/(Loss) Before Exceptional Items & Tax	21.04	71.61
Less: Exceptional & Extra Ordinary Items (Bad Debts)	0	0
Profit/(Loss) Before Tax (PBT)	21.04	71.61
Less: Tax Expense
Current Tax	0	(15.88)
Deferred Tax Liabilities/(Assets)	(12.36)	(2.14)
Earlier year Tax Adjustment	0	0
Net Profit/(Loss) After Tax	8.68	53.59
Earnings Per Equity Share:
Basic	0.14	0.98
Diluted	0.14	0.98

2. RESULTS OF OPERATIONS AND THE STATE OF COMPANYS AFFAIRS

The Revenue from Operations for the Financial Year 2025-26 is Rs. 599.47 lakhs against the previous years revenue of Rs. 317.94 lakhs. The total expenses of the Company during the Financial Year 2025-26 are Rs. 582.62 lakhs against the previous years expenses of Rs. 250.91 lakhs. The Company has earned net profit of Rs. 8.68 lakhs against the previous years Profit of Rs. 53.59 Lakhs.

3. DIVIDEND

During the year under review, your directors have not recommended any Dividend on Equity Shares of the Company with a view to meet future requirements of projects and to strengthen the financial position of the Company.

4. TRANSFER TO RESERVES

During the year under review, your directors have decided not transfer any amount to the general reserve.

5. DEPOSITS

There were no outstanding deposits within the meaning of Section 73 and 74 of the Act, read with rules made thereunder at the end of FY 2025-26 or the previous financial years. Your Company did not accept any deposit during the year under review.

6. EXTRACT OF ANNUAL RETURN

The Annual Return of the Company as on March 31, 2026, in the Form MGT-7 in accordance with Section 92(3) and 134(3)(a) of the Act as amended from time to time and the Companies (Management and Administration) Rules, 2014 is available on the weblink of the Company at www.maplehospital.in under the section Investor Relations.

7. BOARD OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

The Company has a professional Board with Executive Directors & Non-Executive Directors who bring the right mix of knowledge, skills, and expertise and help the Company in implementing the best Corporate Governance practices.

The details of Board of Directors and Key Managerial Personnel of the Company as on March 31, 2026:

Name	Designation	Date of Appointment
Mr. Jaykumar Narendra Vyas	Managing Director	25/04/2023
Mrs. Shachi Jaykumar Vyas	Whole-Time Director	25/04/2023
Mrs. Dhyuti Krupesh Joshi	Chairman & Director	05/10/2023
Mr. Mehul Narendrakumar Hingu	Independent Director	09/12/2023
Mr. Shrikrishna Ramesh Chaudhari	Independent Director	15/12/2023
Mrs. Urvi Mrunal Hindia*	Chief Financial Officer	01/12/2023
Mrs. Swati Sharma#	Company Secretary	21/12/2023

* Resigned w.e.f. 25/08/2026 # Resigned w.e.f. 30/08/2026

8. DECLARATION FROM INDEPENDENT DIRECTORS AND THEIR FAMILIARISATION PROGRAM

The Company has received necessary declaration from each independent director under Section 149(7) of the Companies Act, 2013, that they meet the criteria of independence laid down in Section 149(6), Code for independent directors of the Companies Act, 2013 and they have registered their names in the Independent Directors Databank. All those Independent Directors who are required to undertake the online proficiency self-assessment test as contemplated under Rule 6(4) of the Companies (Appointment and Qualification of Directors) Rules, 2014, have passed such test.

Based on the disclosures received from all independent directors and in the opinion of the Board, the independent directors fulfil the conditions specified in the Act, the Listing Regulations, listing manual and are independent of the Management. In the opinion of the Board, the independent directors so appointed possess requisite integrity, expertise, experience and proficiency.

The Directors are regularly informed during meetings of the Board and its Committees on the activities of the Company, its operations and issues faced by the industry. The details of familiarization programs provided to the Directors of the Company are available on the Companys website www.maplehospital.in.

9. DIRECTORS RESPONSIBILITY STATEMENT

Pursuant to the requirement under section 134(3)(c) and 134 (5) of the Companies Act, 2013, with respect to Directors Responsibility Statement, it is hereby confirmed that:

a. In the preparation of the annual accounts for the year ended March 31, 2026 the applicable accounting standards had been followed along with proper explanation relating to material departures;

b. The Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit of the Company for that year;

c. The Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

d. The Directors have prepared the annual accounts on a going concern basis; and

e. The Directors have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and were operating effectively.

f. The directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

10. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS UNDER SECTION 186 OF THE ACT

Kindly refer the financial statements for the loans, guarantees and investments given/made by the Company as on March 31, 2026.

11. MEETINGS OF THE BOARD OF DIRECTORS

During the year under review, 4 (Four) Board Meetings were held by the Company. All the board meetings have been held within the prescribed time gap of 120 days as per the provisions of Section 173 of the Companies Act, 2013. The Agenda for the Board, General as well as Committee Meetings together with the appropriate supporting documents and relevant information were circulated in advance of the meetings to enable the Board to take informed decisions.

The necessary quorum was present in all the meetings. Leave of absence was granted to concern Directors upon receipt of the request who could not attend the respective Board Meeting. Below given table is showing the number of meetings held during the year under review:

Sr. No.		Attendance
Date of meeting	Total Number of directors associated as on the date of meeting	Number of directors attended	% of attendance
1 30-05-2025	5	5	100.00%
2 29-08-2025	5	5	100.00%
3 14-11-2025	5	5	100.00%
4 10-02-2026	5	5	100.00%

12. COMMITTEES OF THE BOARD

Our Board of Directors presently has four (4) committees which have been constituted/ re-constituted in accordance with the relevant provisions of the Companies Act:

(i) Audit Committee,

(ii) Stakeholders Relationship Committee, (iii) Nomination and Remuneration Committee, and

Meeting of Audit Committee and Relevant Quorum

During the year the Audit Committee met four times in and the gap not more than one hundred and twenty days between two meetings.

Dates of meeting are 30-05-2025, 29-08-2025, 14-11-2025 and 10-02-2026. The quorum for audit committee meeting shall be either two members or one third of the members of the audit committee, whichever is greater, with at least two independent directors.

The composition of the Committee and attendance of the members at the meetings held during the financial year 2025-26 are as follows:

Name of the member	Nature of directorship	Designation in committee	No. of meeting in FY 2025-26
			Held	Attend
Mr. Mehul Narendrakumar Hingu	Non- Executive Independent Director	Chairman	4	4
Mr. Shrikrishna Ramesh Chaudhari	Non- Executive Independent Director	Member	4	4
Mr. Jaykumar Narendra Vyas	Managing Director	Member	4	4

Meeting of Stakeholders Relationship Committee and Relevant Quorum

During the year the Stakeholders Relationship committee met two times in a year and shall report to the Board of Directors regarding the status of redressal of complaints received from the shareholders of the Company.

Dates of meeting are 30-05-2025 and 14-11-2025. The quorum for a meeting of the Stakeholders Relationship Committee shall be two members present.

The composition of the Committee and attendance of the members at the meetings held during the financial year 2025-26 are as follows:

Name of the member	Nature of directorship	Designation in committee	No. of meeting in FY 2025-26
			Held	Attend
Mr. Shrikrishna Ramesh Chaudhari	Non- Executive Independent Director	Chairman	2	2
Mr. Jaykumar Narendra Vyas	Managing Director	Member	2	2
Mrs. Shachi Jaykumar Vyas	Whole-time Director	Member	2	2

Meeting of Nomination and Remuneration Committee and Relevant Quorum

During the year the Stakeholders Relationship committee met One times. Date of meeting was 30-05-2025.

The quorum for Nomination and Remuneration committee meeting shall either be two members or one third of the members of the committee, whichever is greater.

The composition of the Committee and attendance of the members at the meetings held during the financial year 2025-26 are as follows:

Name of the member	Nature of directorship	Designation in committee	No. of meeting in FY 2025-26
			Held	Attend
Mr. Shrikrishna Ramesh Chaudhari	Non- Executive Independent Director	Chairman	1	1
Mr. Mehul Narendrakumar Hingu	Non- Executive Independent Director	Member	1	1
Mrs. Dhyuti Krupesh Joshi	Non- Executive Director	Member	1	1

13. CHANGE IN NATURE OF BUSINESS, IF ANY

There was no change in the nature of business of the Company during the year under review.

14. DETAILS OF SUBSIDIARY, JOINT VENTURE AND ASSOCIATE COMPANY

During the year under review, the Company does not have any Subsidiary, Joint Venture & Associate Company.

15. SHARE CAPITAL

The Company has an Authorized Capital of Rs. 6,10,00,000 divided into 61,00,000 Equity Shares of Rs. 10 each. The Company has Issued, Subscribed and Paid-up Capital of Rs. 6,07,03,800 divided into of face value of Rs. 10 each.

16. MATERIAL CHANGES AND COMMITMENTS, IF ANY, AFFECTING THE FINANCIAL POSITION OF THE COMPANY

There have been no material changes and commitments, affecting the financial position of the Company subsequent to the close of FY 2025-26 till the date of this report.

17. PARTICULARS OF EMPLOYEES

Disclosures relating to remuneration and other details as required under section 197(12) of the Companies Act, 2013 read with rules 5(1), 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, is annexed herewith as Annexure-A and forms part of this Boards report.

18. STATUTORY AUDITORS

Present statutory Auditor M/s. K. K. Haryani & Co., Chartered Accountants (FRN: 121950W) were reappointed at first Annual general meeting held on 1st July, 2024 to hold office till conclusion of Sixth Annual General meeting of the company.

The Statutory Auditors have confirmed that they are not disqualified to continue as Statutory Auditors and are eligible to hold office as Statutory Auditors of your Company. The company had received eligibility certificate from the auditor.

The Auditors Report does not contain any qualification or adverse remark. Notes to Accounts and Auditors remarks in their report are self-explanatory and do not call for any further comments.

19. AUDITORS REPORT AND BOARDS COMMENTS THEREON

The Statutory Auditors of the Company have submitted the Audit Report for the financial year 2025-26. The Auditors report does not contain any qualification, reservation or adverse remarks. The notes on financial statement referred to in the Auditors report are self-explanatory and do not call for any comments.

20. DISCLOSURE OF ACCOUNTING TREATMENT

In the preparation of the financial statements, the Company has followed the Accounting Standards referred to in Section 133 of the Companies Act, 2013. The significant accounting policies which are consistently applied are set out in the Notes to the Financial Statements.

21. INTERNAL AUDITOR AND REPORT

During the year under review, Board of Directors of the Company in their meeting held on 14 th November, 2025 has appointed M/s. R. M. Hariyani & Co, Chartered Accountant (FRN 147657W) as an internal auditor of the company for FY 2025-26 and has conducted periodic audit of all operations of the Company. The Audit Committee has reviewed the findings of Internal Auditors regularly.

22. SECRETARIAL AUDITOR, SECREATARIAL AUDIT REPORT AND MANAGEMENT REPRESENTATION ON QUALIFICATION, RESERVATION OR ADVERSE REMARKS

During the year under review, M/s. N R Shah & Co., Practicing Company Secretaries, was appointed as the Secretarial Auditor of the Company for the financial year 2025-26 by the Board of Directors at its meeting held on November 14, 2025, pursuant to the applicable provisions of the Companies Act, 2013 and the rules made thereunder.

Subsequently, M/s. N R Shah & Co., Practicing Company Secretaries, resigned from the office of Secretarial Auditor of the Company with effect from August 13, 2026.

Pursuant to the provisions of Section 204 of the Companies Act, 2013 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, a casual vacancy arose in the office of the Secretarial Auditor of the Company. Accordingly, the Board of Directors of the Company, at its meeting held on August 26, 2026, appointed M/s. Rahul S. Mithaiwala & Co., Practicing Company Secretary (Peer Review No.: 1910/2022, Membership No.: FCS F11556), as the Secretarial Auditor of the Company to fill the said casual vacancy and to conduct the Secretarial Audit of the Company for the financial year 2025-26, subject to such approvals as may be required under the applicable provisions of the Companies Act, 2013 and the rules made thereunder.

Further, in terms of Section 204 of the Act and Regulation 24A of the SEBI Listing Regulations, the Board of Directors has, on the recommendation of the Audit Committee, approved the appointment of M/s. Rahul S. Mithaiwala & Co., Practicing Company Secretary (Peer Review No.: 1910/2022, Membership No.: FCS F11556), as the Secretarial Auditors of the Company, to hold office for a term of five (5) consecutive years with effect from financial year 2026-27 to financial year 2030-31, subject to approval of the Members of the Company at the ensuing AGM. Accordingly, a resolution seeking Members approval for appointment of Secretarial Auditors of the Company forms part of the Notice of the AGM forming part of this Annual Report.

The Secretarial Audit Report for the financial year 2025-26 in Form MR-3 is attached to this report as Annexure-B . The Secretarial Auditors Report contains certain observations/qualifications. The Board has taken note of the observations/qualifications made by the Secretarial Auditor in the said Report. The remarks made therein are self-explanatory. The Board has duly evaluated the observations/qualifications and the Company is committed to taking appropriate corrective steps to address the same and ensure timely compliance with the applicable provisions in due course in future.

23. REPORTING OF FRAUDS

There was no instance of fraud during the year under review, which required the Statutory Auditors or Secretarial Auditors to report to the Audit Committee, Board and/ or Central Government under Section 143(12) of the Companies Act, 2013 and Rules framed there under.

24. SECRETARIAL STANDARDS

The Directors state that applicable Secretarial Standards, i.e. SS-1 and SS-2, relating to Meetings of the Board of Directors and General Meetings, respectively, have been duly followed by the Company.

25. DISPATCH OF ANNUAL REPORT THROUGH ELECTRONIC MODE

In compliance with various MCA Circulars and SEBI Circulars, the notice of the AGM along with the Annual Report 2025-26 is being sent only through electronic mode to those members whose email addresses are registered with the Company/RTA/Depositories. Members may note that the Notice and Annual Report 2025-26 will also be available on the Companys website at www.maplehospital.in, websites of the Stock Exchange, i.e., BSE Limited at www.bseindia.com and on the website of NSDL (agency for providing the Remote e-Voting facility) i.e. www.evoting.nsdl.com.

26. CORPORATE GOVERNANCE

Since the Companys securities are listed on SME Platform of BSE, by virtue of Regulation 15 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 the compliance with the Corporate Governance provisions as specified in Regulations 17 to 27 and clauses (b) to (i) of sub-regulation (2) of Regulation 46 and para C, D and E of Schedule V are not applicable to the Company.

27. CORPORATE SOCIAL RESPONSIBILITY

The provision of Section 135 of Companies Act, 2013 and rules made thereunder are not applicable to our Company for the financial year ended 31 st March, 2026.

28. DETAILS ON CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS

& OUTGO a) Conservation of Energy, Technology Absorption Conservation of energy:

1 The steps taken or impact on conservation of energy.	The Company exercised the strict control in its operations to minimize the power cost and reduce the waste of energy.
2 The steps taken by the company for utilizing alternate sources of energy.	N. A.
3 The capital investment on energy conservation equipments.	N. A.

Technology Absorption:

1 Efforts in brief, made towards technology absorption, adaptation and innovation	None
2 Benefits derived as a result of the above efforts	N. A.
3 Information Regarding Imported Technology	N. A.
4 Expenditure Incurred on R & D	N. A.

Foreign exchange earnings and Outgo

Particulars	Amount in Lakhs
Earnings	NIL
Outgo	NIL

29. LISTING FEES

The Equity Shares of the Company are listed on SME Platform of BSE Limited and The Company has paid the applicable listing fees to the Stock Exchange till date.

30. MANAGEMENT DISCUSSIONS & ANALYSIS REPORT

The Management Discussion and Analysis report has been separately furnished in the Annual Report and forms a part of the Annual Report. Same is annexed as Annexure-C .

31. COST AUDIT APPLICABILITY

Maintenance of cost records under sub-section (1) of section 148 of the Companies Act, 2013 are not applicable to the Company.

32. GENERAL

Your directors state that no disclosure or reporting is required in respect of the following items as there were no transactions on these items during the year under review:

(a) Issue of equity shares with differential rights as to dividend, voting or otherwise.

(b) Issue of shares (including sweat equity shares) to employees of the Company under any scheme.

33. DETAILS OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS

The Company has an Internal Control System, commensurate with the size, scale and complexity of its operations. The scope and authority of the Internal Audit function is well defined in the organization. The Internal Audit Department monitors and evaluates the efficacy and adequacy of Internal Control Systems in the Company, its compliance with operating systems, accounting procedures and policies at all locations of the Company. Based on the report of Internal Audit function, process owners undertake corrective action in their respective areas and thereby strengthen the controls. Significant audit observations and corrective actions suggested are presented to the Audit Committee of the Board.

34. FORMAL ANNUAL EVALUATION

Pursuant to the provision of the Companies Act, 2013 and Rules made thereunder, the Board has carried the evaluation its own performance, performance of individual directors, Board Committees, including the Chairman of the Board on the basis of attendance, contribution and various criteria as recommended by the Nomination and Remuneration Committee of the Company. The evaluation of the working of the Board, its committees, experience and expertise, performance of specific duties and obligation etc. were carried out. The overall outcome of the board evaluation process was positive and the Directors expressed their satisfaction with the evaluation process and outcome.

In a separate meeting of Independent Directors, performance of Non-Independent Directors, the Board as a whole and Chairman of the Company was evaluated, taking into account the views of Executive and Non-Executive Directors.

35. RELATED PARTY TRANSACTION

All related party transactions entered into by the Company during the Financial Year 2025-26 were in the ordinary course of business and on an arms length basis. The transactions with related parties were conducted in a transparent manner, with the interest of the Company and its stakeholders being accorded the utmost priority.

During the Financial Year 2025-26, the Company has no material related party transactions or transactions not on arms length, requiring disclosure under Section 134(3)(h) of the Companies Act, 2013, in Form AOC-2 attached to this report as Annexure-D. The details of related party transactions, as applicable, are disclosed in the Notes to the Financial Statements.

36. VALUATION

During the year, there were no instances of Onetime Settlement with any Banks or Financial Institutions.

37. THE DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 (31 OF 2016) DURING THE YEAR ALONGWITH THEIR STATUS AS AT THE END OF THE FINANCIAL YEAR

During the year, there was no application made or any proceeding pending under the Insolvency and Bankruptcy Code, 2016 (31 of 2016).

38. NOMINATION AND REMUNERATION POLICY

In accordance with the provisions of Section 178 of the Companies Act, 2013, the Board of Directors of the Company has adopted the Nomination and Remuneration Policy (the Policy). The Policy, inter alia, provides guidelines for the appointment, removal and remuneration of the Directors, Key Managerial Personnel and Senior Managerial Personnel of the Company. The said policy can be downloaded from the web link: https://www.maplehospital.in/Investor-Relations.aspx.

39. DISCLOSURE UNDER SEXUAL HARASSEMENT OF WOMAN AT WORKPLACE (PREVENTION, PROHIBITION & REDRESAL) ACT, 2013

The Company has adopted a policy on prevention, prohibition, and redressal of sexual harassment at the workplace, in line with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

In line with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013, the Company is duly constituted an Internal Complaints Committee (ICC) to redress complaints, if any, regarding sexual harassment.

During the financial year under review, no complaint was received by the Committee under the said Act.

40. COMPLIANCE WITH THE MATERNITY BENEFIT ACT, 1961

The Company has complied with the provisions of the Maternity Benefit Act, 1961, including all applicable amendments and rules framed thereunder. The Company is committed to ensuring a safe, inclusive, and supportive workplace for women employees. All eligible women employees are provided with maternity benefits as prescribed under the Maternity Benefit Act, 1961, including paid maternity leave, nursing breaks, and protection from dismissal during maternity leave. The Company also ensures that no discrimination is made in recruitment or service conditions on the grounds of maternity. Necessary internal systems and HR policies are in place to uphold the spirit and letter of the legislation.

41. RISK MANAGEMENT

The management continuously access the risk involved in the business and all out efforts are made to mitigate the risk with appropriate action. The risk management framework of the Company is appropriate compared to the size of the Company and the environment under which the Company operates. As part of the Risk Management, the relevant parameters for protection of the environment, safety of operations and health of people at work are monitored regularly.

42. ENVIRONMENT AND SAFETY

The Company is conscious of the importance of environmentally clean and safe operations. The Companys Policy requires conduct of operations in such a manner, so as to ensure the safety of all concerned, compliances of environmental regulations and preservation of natural resources.

43. VIGIL MACHANISM/ WHISTLEBLOWER

In compliance with the provisions of Section 177(9) of the Companies Act, 2013, the Board of Directors of the Company has framed the Whistle Blower Policy as the vigil mechanism for Directors and employees of the Company. In compliance with the provisions of Section 177(9) of the Companies Act, 2013, the Board of Directors of the Company has framed the Whistle Blower Policy as the vigil mechanism for Directors and employees of the Company. The Whistle Blower Policy is disclosed on the website of Company.

44. SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS

During the year under review, there has been no significant and material order passed by any Regulators or Courts or Tribunals, impacting the going concern status of the Company and its future operations.

45. HUMAN RESOURCES

The Company treats its Human Resources as one of its most important assets. The Companys culture promotes an environment that is transparent, flexible, fulfilling and purposeful. The Company is driven by a passionate and highly engaged workforce. This is evident from the fact that the Company continues to remain the industry benchmark for talent retention.

Your Company continuously invests in attraction, retention and development of talent on an ongoing basis. A number of programs that provide focused people attention are currently underway. The Company thrust is on the promotion of talent internally through job rotation and job enlargement.

During the year under review, there was a cordial relationship with all the employees. The Directors would like to acknowledge and appreciate the contribution of all employees towards the performance of the Company.

46. INVESTORS EDUCATION AND PROTECTION FUND

During the year, there was no unclaimed and unpaid dividend and corresponding equity shares on which dividends were unclaimed/unpaid for seven consecutive years which was required to be transferred as per the requirement of the IEPF Rules.

47. BOARD DIVERSITY

The Company has over the years been fortunate to have eminent people from diverse fields to serve as Directors on its Board. Pursuant to the SEBI Listing Regulations, the Nomination & Remuneration Committee of the Board ensured diversity of the Board in terms of experience, knowledge, perspective, background, gender, age and culture.

48. ACKNOWLEDGEMENT

Your directors take this opportunity to place on record the appreciation of the valuable contribution and dedication shown by the employees of the Company, RTA, Auditors and Practicing Company Secretary which have contributed to the successful management of the Companys affairs. The Directors also take this opportunity to thank all the Stakeholders, Investors, Clients, Banks, Government, Regulatory Authorities and Stock Exchange for their continued support.

By Order of the Board of Directors
Broach Lifecare Hospital Limited

Shachi Jaykumar Vyas	Jaykumar Narendra Vyas
Whole-time director	Managing Director
DIN: 09063799	DIN: 08736387

Date: September 5, 2026
Place: Bharuch